JAKARTA - The IndoVac COVID-19 vaccine produced by PT Bio Farma (Persero), Pharmaceutical BUMN Holding, has officially received a halal certificate from the Halal Product Guarantee Agency (BPJPH). The company will export the vaccine in the near future.
"Alhamdulillah, the IndoVac Vaccine has officially obtained Fatwa and Halal Decree from MUI which was later used as the basis for the issuance of a Halal Certificate by BPJPH. We ensure that all processes and production chains of the IndoVac Vaccine, from raw materials and processes to finished products, have met the requirements of halal products. IndoVac has met the needs of halal aspects and thayyib which strengthens quality and safety guarantees for this vaccine," said Honesti Basyir, President Director of Bio Farma in a statement, Antara, Thursday, October 6.
In addition, the IndoVac vaccine production facility has already received a Good Manufacturing Practice (CPOB) certificate from the Food and Drug Administration (BPOM) on April 9, 2022. Meanwhile, quality data, potential, production processes of active substances, finished products, and stability have also been in accordance with the BPOM policy.
Based on Law no. 33/2014 concerning Halal Product Guarantee, the certification of a product aims to provide comfort, security, safety, and certainty over the availability of halal products for the community.
According to him, halal certification is one of the advantages of IndoVac in the global market after obtaining Emergency Use Listing (EUL) from the World Health Organization (WHO).
"In addition to obtaining an emergency use permit (EUA) from BPOM on September 29, 2022, Bio Farma is registering EUL with WHO in order to fulfill requests from abroad. Of course, halal certificates are added value, especially for Muslim markets."
Bio Farma has carried out clinical trials of IndoVac Vaccine stages 1, 2, and 3 in accordance with BPOM standards, with results such as efficacy, security, and good immunogenicity.
IndoVac's security can be seen from the results of clinical trials with Post-Immunization Adverse Events (AEFI) which are mild in nature, in the form of local pain around the injection area with no serious intensity.
In addition, the IndoVac Vaccine is also able to increase antibody titers, thereby reducing one's risk of being infected with COVID-19.
The English, Chinese, Japanese, Arabic, and French versions are automatically generated by the AI. So there may still be inaccuracies in translating, please always see Indonesian as our main language. (system supported by DigitalSiber.id)
